Cefepime-resistant pseudomonas Aeruginosa

Ehimare Akhabue, Marie Synnestvedt, Mark G. Weiner, Warren B. Bilker, Ebbing Lautenbach*

*Corresponding author for this work

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case-control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001-2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepimeresistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p =0.001). Strategies to counter its emergence should focus onoptimizing use of antipseudomonal drugs.

Original languageEnglish (US)
Pages (from-to)1037-1043
Number of pages7
JournalEmerging Infectious Diseases
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2011

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Epidemiology

Fingerprint Dive into the research topics of 'Cefepime-resistant pseudomonas Aeruginosa'. Together they form a unique fingerprint.

  • Cite this

    Akhabue, E., Synnestvedt, M., Weiner, M. G., Bilker, W. B., & Lautenbach, E. (2011). Cefepime-resistant pseudomonas Aeruginosa. Emerging Infectious Diseases, 17(6), 1037-1043. https://doi.org/10.3201/eid1706.100358